BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 17574991)

  • 1. Radiopharmaceutical chemistry of targeted radiotherapeutics, Part 3: alpha-particle-induced radiolytic effects on the chemical behavior of (211)At.
    Pozzi OR; Zalutsky MR
    J Nucl Med; 2007 Jul; 48(7):1190-6. PubMed ID: 17574991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiopharmaceutical chemistry of targeted radiotherapeutics, Part 2: radiolytic effects of 211At alpha-particles influence N-succinimidyl 3-211AT-astatobenzoate synthesis.
    Pozzi OR; Zalutsky MR
    J Nucl Med; 2005 Aug; 46(8):1393-400. PubMed ID: 16085599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiopharmaceutical chemistry of targeted radiotherapeutics, part 1: effects of solvent on the degradation of radiohalogenation precursors by 211At alpha-particles.
    Pozzi OR; Zalutsky MR
    J Nucl Med; 2005 Apr; 46(4):700-6. PubMed ID: 15809494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiopharmaceutical chemistry of targeted radiotherapeutics, part 4: Strategies for
    Pozzi OR; Zalutsky MR
    Nucl Med Biol; 2017 Mar; 46():43-49. PubMed ID: 28013121
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-level production of alpha-particle-emitting (211)At and preparation of (211)At-labeled antibodies for clinical use.
    Zalutsky MR; Zhao XG; Alston KL; Bigner D
    J Nucl Med; 2001 Oct; 42(10):1508-15. PubMed ID: 11585865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biodistribution of 211At labeled HER-2 binding affibody molecules in mice.
    Steffen AC; Almqvist Y; Chyan MK; Lundqvist H; Tolmachev V; Wilbur DS; Carlsson J
    Oncol Rep; 2007 May; 17(5):1141-7. PubMed ID: 17390057
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Labeling Monoclonal Antibody with α-emitting
    Vaidyanathan G; Pozzi OR; Choi J; Zhao XG; Murphy S; Zalutsky MR
    Cancer Biother Radiopharm; 2020 Sep; 35(7):511-519. PubMed ID: 32109139
    [No Abstract]   [Full Text] [Related]  

  • 8. Direct procedure for the production of 211At-labeled antibodies with an epsilon-lysyl-3-(trimethylstannyl)benzamide immunoconjugate.
    Lindegren S; Frost S; Bäck T; Haglund E; Elgqvist J; Jensen H
    J Nucl Med; 2008 Sep; 49(9):1537-45. PubMed ID: 18703591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reagents for astatination of biomolecules: comparison of the in vivo distribution and stability of some radioiodinated/astatinated benzamidyl and nido-carboranyl compounds.
    Wilbur DS; Chyan MK; Hamlin DK; Kegley BB; Risler R; Pathare PM; Quinn J; Vessella RL; Foulon C; Zalutsky M; Wedge TJ; Hawthorne MF
    Bioconjug Chem; 2004; 15(1):203-23. PubMed ID: 14733601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of At- species in simple and biological media by high performance anion exchange chromatography coupled to gamma detector.
    Sabatié-Gogova A; Champion J; Huclier S; Michel N; Pottier F; Galland N; Asfari Z; Chérel M; Montavon G
    Anal Chim Acta; 2012 Apr; 721():182-8. PubMed ID: 22405318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the 210At impurity in the production of 211At for radiotherapy by 210Po analysis via isotope dilution alpha spectrometry.
    Schultz MK; Hammond M; Cessna JT; Plascjak P; Norman B; Szajek L; Garmestani K; Zimmerman BE; Unterweger M
    Appl Radiat Isot; 2006; 64(10-11):1365-9. PubMed ID: 16563782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reagents for astatination of biomolecules. 2. Conjugation of anionic boron cage pendant groups to a protein provides a method for direct labeling that is stable to in vivo deastatination.
    Wilbur DS; Chyan MK; Hamlin DK; Vessella RL; Wedge TJ; Hawthorne MF
    Bioconjug Chem; 2007; 18(4):1226-40. PubMed ID: 17583925
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fully automated preparation of n.c.a. 4-[18F]fluorobenzoic acid and N-succinimidyl 4-[18F]fluorobenzoate using a Siemens/CTI chemistry process control unit (CPCU).
    Marik J; Sutcliffe JL
    Appl Radiat Isot; 2007 Feb; 65(2):199-203. PubMed ID: 16935516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthetic approaches and bio-distribution studies of [11C]methyl-phenidate.
    Patt M; Solbach C; Wüllner U; Blocher A; Stahlschmidt A; Gündisch D; Kovar KA; Machulla HJ
    J Pharm Pharm Sci; 2007; 10(2):312s-320s. PubMed ID: 17718934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiation-induced thyroid stunning: differential effects of (123)I, (131)I, (99m)Tc, and (211)At on iodide transport and NIS mRNA expression in cultured thyroid cells.
    Lundh C; Lindencrona U; Postgård P; Carlsson T; Nilsson M; Forssell-Aronsson E
    J Nucl Med; 2009 Jul; 50(7):1161-7. PubMed ID: 19525464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy.
    Zalutsky MR; Vaidyanathan G
    Curr Pharm Des; 2000 Sep; 6(14):1433-55. PubMed ID: 10903402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study.
    Andersson H; Cederkrantz E; Bäck T; Divgi C; Elgqvist J; Himmelman J; Horvath G; Jacobsson L; Jensen H; Lindegren S; Palm S; Hultborn R
    J Nucl Med; 2009 Jul; 50(7):1153-60. PubMed ID: 19525452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior.
    Dekempeneer Y; Bäck T; Aneheim E; Jensen H; Puttemans J; Xavier C; Keyaerts M; Palm S; Albertsson P; Lahoutte T; Caveliers V; Lindegren S; D'Huyvetter M
    Mol Pharm; 2019 Aug; 16(8):3524-3533. PubMed ID: 31268724
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-succinimidyl 3-[(131)I]iodo-4-phosphonomethylbenzoate ([(131)I]SIPMB), a negatively charged substituent-bearing acylation agent for the radioiodination of peptides and mAbs.
    Shankar S; Vaidyanathan G; Affleck D; Welsh PC; Zalutsky MR
    Bioconjug Chem; 2003; 14(2):331-41. PubMed ID: 12643743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.